Login / Signup

Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.

Shu-Kai ZhanCaiguang LiuNa LiTong LiZhenyi TianMin ZhaoDongxuan WuMin-Hu ChenZhirong ZengXiaojun Zhuang
Published in: Therapeutic advances in gastroenterology (2022)
Behçet's disease (BD) is a disease affecting several organs including the gastrointestinal tract. Nowadays, the efficacy of existing therapy strategies is still unsatisfactory and some patients are suffering from repeated attacks of the disease. We noticed that a new kind of medicine, called antitumor necrosis factor alpha (anti-TNF-α) agents, was applied to these patients recently. The therapeutic efficacy is not convincing enough to evaluate since the number of patients receiving this new medicine was small in every individual study. Regarding this, we conducted a research to learn about the efficacy of this medicine at our own institution. Besides, we composed the results of other studies in an appropriate way. Then, we drew a conclusion on the exact efficacy of anti-TNF-α agents after the data analysis. We unveiled that the anti-TNF-α agents appeared both effective and safe in the management of intestinal BD patients when the classical therapy failed. More than half of the patients could achieve discomfort remission when they got the therapy of the new medicine at our institution. We also found that intestinal ulcers in most patients improved after they received the treatment. All in all, it offered another foothold for getting relief in these patients who were caught in this mire.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • rheumatoid arthritis
  • stem cells
  • mesenchymal stem cells
  • systemic lupus erythematosus
  • patient reported
  • disease activity